A 28-day treatment trial was undertaken, to determine the efficacy of chloroquine in Laos and to assess the predictive value of molecular markers (cg2, pfmdr1, and pfcrt) that were previously linked to chloroquine resistance. In total, 522 febrile patients were screened for falciparum malaria by rapid diagnostic assays. Of 81 patients (15.5% prevalence) who were positive by the assays and microscopy, 48 were eligible to participate in the 28-day trial. Nine patients defaulted. Chloroquine cured 54% (95% confidence interval, 45.8-61.8) of falciparuminfected patients. Of 18 (46%) patients with treatment failure, 13 (72%) experienced high-grade resistance. Polymorphisms in cg2 and the N86Y mutation in PfMDR1 were not predictive of treatment outcome. A mutation in PfCRT (K76T) was perfectly associated with in vivo chloroquine resistance. However, K76T was also present in in vivo-sensitive isolates, which suggests that the presence of this mutation was necessary, but not sufficient, to predict in vivo outcome in this cohort.
Chloroquine-resistant Plasmodium falciparum was first described in Southeast Asia in 1959 and has since become widespread in this region [1] . The emergence of chloroquine-resistant malaria has necessitated the escalating use of more-potent and expensive antimalarials. In turn, this has resulted in the emergence of drug resistance to these newer agents [2] . The use of chloroquine as a first-line agent for the treatment of falciparum malaria was abandoned in Thailand by 1973 [2, 3] . Despite being landlocked by nations with multidrug-resistant malaria, Laos (Lao People's Democratic Republic) continues to use chloroquine as first-line therapy for uncomplicated malaria.
There have been no in vivo treatment trials reported to support or refute the current use of chloroquine, although earlier observations suggest that chloroquine-resistant falciparum malaria exists [4] [5] [6] [7] . Moreover, within the last decade there has been increased movement of people across Laotian borders that might facilitate the importation of drug-resistant malaria. In vivo treatment trials of chloroquine efficacy require an accurate and rapid diagnosis of falciparum malaria, an appropriate dose of chloroquine administered under supervision, monitoring of enrolled patients for both clinical and parasitologic response, and, ideally, the use of genetic polymorphism analysis to ensure that recurrent infections result from recrudescence and not from reinfection [8] [9] [10] [11] .
The objectives of this study were 2-fold: to determine the appropriateness of chloroquine as first-line therapy for falciparum malaria in a selected region of Laos and to assess the predictive value of molecular markers (cg2 and pfmdr1) of P. falciparum that have been linked to chloroquine resistance and a P. falciparum gene (pfcrt) that more recently was implicated in chloroquine resistance [12] [13] [14] . We used new rapid diagnostic tests in the field to identify falciparum-infected patients for enrollment in a 28-day in vivo chloroquine treatment trial.
Patients, Materials, and Methods
Selection of study site. Laos is a developing country (per capita gross national product, $370; per capita gross domestic product, $1775) of ∼4.5 million people, and 80% of the population live in rural areas. In 1997, 3.77 million people were at risk for malaria, 370,529 clinically diagnosed cases were reported, and the nationwide incidence was estimated at 462,000 [15] . In 1998, parasitologic screening in all 17 provinces found 36,172 of 253,305 blood films positive for all Plasmodium species, which suggests a countrywide prevalence rate of 14.2% (provincial range, 3.4%-42.7%) [15] .
With Ministry of Health (Laos) approval, the study sites were chosen in Vang Vieng District, Vientiane Province, where ∼190,000 persons are at risk for malaria [15] . Study sites were chosen on the basis of preliminary small-scale trials performed since 1990 that found evidence of increasing in vivo chloroquine-resistant falciparum malaria (V. Vanisaveth, unpublished data). We focused on 12 villages in this district, where several ethnic groups-mostly Lao Loum, Lao Theung, and Lao Soong-do subsistence farming. Local anopheline species include Anopheles minimus, A. dirus, and A. maculatus [15] .
Study population. Populations eligible for the study were residents of 12 villages in Vang Vieng District who presented to provincial Institute for Malariology, Parasitology, and Entomology (IMPE; Vientiane, Laos) malaria clinics with fever or prior fever within 48 h between 15 October 1998 and 30 July 1999. Patients were excluded if they were pregnant, were !1 year old, had diarrhea (у3 loose stools per day), gave a history of ingestion of antimalarials in the preceding month, or had a history of chloroquine intolerance. Sample size determination was done by the lot quality assurance sampling (LQAS) method [16] . An upper threshold of clinical treatment failures was set at 25%, as an indication for replacement of chloroquine as first-line therapy. Thus, by the LQAS method, 15 treatment failures in an initial sample size (n 1 ) of 16 was sufficient to assert (95% confidence level, 80% power) that the proportion of clinical failures was not significantly !25% in this population [16] .
Specimen collection and rapid diagnostic assays. We collected whole blood specimens (100 mL) before treatment by fingerprick with sterile lancets. These specimens were used for Giemsa-stained thick and thin smears for rapid malaria diagnosis by 2 dipstick assays (PATH [assay 1] and OptiMAL [Flow; assay 2]) and for polymerase chain reaction (PCR) template preparation filter paper (IsoCode Stix; Schleicher and Schuell). Dipstick assay 1 detects parasite histidine-rich protein (HRPII), and dipstick assay 2 detects parasite lactate dehydrogenase. Both rapid diagnostic assays were performed and interpreted in the field on fresh nonanticoagulated whole blood, as recommended by the manufacturers. Both were interpreted independently, without the interpreter's being aware of the results of other diagnostic assays. Thick and thin smears were sent to a reference center (IMPE) and were read by experienced microscopists, using light microscopy (oil immersion magnification, ϫ1000; у100 oil-immersion fields were examined before a slide was determined to be negative). Microscopists were unaware of the results of the rapid diagnostic assays. Parasite count was determined as parasite count per 200 white blood cells ϫ40 and was expressed as parasites per microliter [17] . DNA template filter papers were sent to the University of Toronto for subsequent parasite DNA extraction and amplification.
Conduct of in vivo clinical trial. All patients who presented with fever or history of fever (within 48 h) were screened for malaria by rapid diagnostic assays. Patients who tested positive by dipstick for P. falciparum were confirmed by thick and thin smears and were invited to participate in a 28-day in vivo trial. Those who agreed to participate received directly observed therapy with a standard treatment course of chloroquine (25 mg base/kg over 48 h). Drug doses were administered and documented by a team member. Patients were seen at follow-up by the study team, and patients with persistent fever or recurrence of symptoms had repeat blood smears and samples collected for PCR analysis. In addition, repeat blood smears and whole blood samples (100 mL) for PCR analysis were collected from participants on days 7, 14, and 28. Patients in whom treatment failed were admitted to the Vang Vieng district hospital and were given intravenous quinine dihydrochloride, according to Laos public health policy [18] . Whole blood filter paper samples for PCR analysis were stored in individual plastic bags with desiccant at ambient temperature until analysis. All follow-up thick and thin blood smears were examined by an expert microscopist for у200 thick film fields (magnification, ϫ1000).
PCR-based species identification and genotyping. Parasite genomic DNA was extracted from filter paper, as described elsewhere, with modification of the manufacturer's guidelines (K. Zhong, C. J. Salas, R. Shafer, A. Gubanov, R. A. Gasser, Jr., A. Magill, J. R. Forney, K. C. Kain, unpublished data). PCR-based species identification was done as described elsewhere ( [8] and authors' unpublished data). To distinguish true treatment failures from new infections, paired primary and recurrent isolates were analyzed by PCR single-strand conformational polymorphism (SSCP) analysis, as described elsewhere [19, 20] . In brief, a portion of the msp1 and msp2 gene from paired isolates was amplified by PCR analysis and was analyzed by SSCP analysis. The SSCP banding pattern of the recurrent isolate was compared with its matched primary isolate. Our criterion for identity was that the mobility of each SSCP band in the recurrent isolate had to match a corresponding band in the primary isolate, indicating a true treatment failure. Nonidentity indicated a new infection [19, 20] . Genetic polymorphism analysis was only done on paired primary and recurrent isolates when the recurrent isolate occurred 114 days after reinfection, because reinfection before day 14 was considered to be unlikely [21] .
Molecular analysis of resistance markers. Polymorphisms of cg2 were analyzed by sequencing (T7 Sequenase PCR sequencing kit; Amersham Life Sciences). Oligonucleotide primers were designed to correspond to highly conserved DNA sequences flanking 2 variable regions of cg2 (802-1247 and 5866-6766; GenBank accession no. AF030693). PCR-restriction fragment length polymorphism (RFLP) analysis was done on the region spanning the tyrosine 86 allele of pfmdr1 (GenBank accession no. X56851). PCR amplification of the pfmdr1 locus was followed by restriction digestion with AflIII and ApoI (both New England Biolabs), as described elsewhere [13] . With this strategy, asparagine (N) to tyrosine (Y) mutations at residue 86 that have been associated with chloroquine resistance were identified. Restriction digests for pfmdr1 were analyzed by 2% agarose gel electrophoresis stained with ethidium bromide and were viewed under UV transillumination. We used a nested PCR-RFLP strategy to identify K76T point mutations in the chloroquine-resistant marker pfcrt (GenBank accession no. AF030694) [14, 22] . Primer sequences and amplification conditions required were provided by Christopher V. Plowe (University of Maryland, Baltimore) and Thomas E. Wellems (National Institutes of Health, Bethesda, MD). Posttreatment failure isolates that were initially "sensitive" for pfmdr1 (N86) or pfcrt (K76) were subjected to repeat PCR-RFLP analysis, to examine in vivo drug selection effects.
End points. The parasitologic end points were classified as either sensitive or resistant (RI, RII, or RIII) as follows [13, 21] : sensitive, complete and sustained clearance of asexual parasitemia by day 28; RI, complete clearance of asexual parasitemia by day 7 but recrudescence within 28 days of initiation of therapy; RII, marked reduction (175%) of asexual parasitemia by 48 h but no clearance by day 7; RIII, no marked reduction of parasitemia by 48 h [13, 21] . To differentiate new infections from recrudescent infections, recurrent isolates identified during days 14-28 were analyzed by PCR-SSCP analysis, as described above. Matching DNA patterns between primary and recurrent isolates indicated true treatment failure; nonmatching patterns indicated reinfection [19, 20] . Statistical analysis. Data were entered and analyzed with EpiInfo 6.0 software (Centers for Disease Control and Prevention).
Results
In vivo treatment trial results. Because rapid and accurate microscopic diagnosis of malaria is frequently unavailable in rural areas with malaria transmission, we used rapid malaria diagnostic dipstick assays to identify potential participants for this in vivo treatment trial. This strategy permitted rapid and accurate identification of falciparum-infected patients in a field setting. A blinded comparison of the 2 dipstick assays with reference microscopy was done to validate the use of these assays in the field. Both assays were highly sensitive (assay 1, 96.7%, and assay 2, 91.8%) and specific (assay 1, 94.4%, and assay 2, 100%) in this tropical field setting (authors' unpublished data).
We screened 522 patients with fever or a history of fever for falciparum malaria. Of these, 81 were positive for P. falciparum (prevalence, 15.5%). Fifty-eight patients with no history of antimalarial use in the preceding month initially agreed to participate in an in vivo chloroquine treatment trial. Ten had evidence of complicated malaria at presentation and were treated with parenteral quinine rather than chloroquine [18] . Forty-eight patients initially entered the 28-day in vivo clinical trial to test for the efficacy of chloroquine (table 1) . Of the 48, 39 received supervised therapy with chloroquine (25 mg base/kg over 48 h) and successfully completed 28 days of follow-up with repeat clinical assessment, blood smears, and blood for PCR analysis on days 7, 14, and 28 or day of recurrence of symptoms.
Chloroquine cured 21 (54%) of 39 patients (95% confidence interval [CI], 45.8-61.8). Eighteen patients (46%; 95% CI, 30.5-61.7) had recurrent parasitemia during the 28-day followup. Of the 39 patients, 13 had persistent asexual stage parasites at day 7, which is consistent with RII/RIII resistance. Five patients (12.8%) had recurrences during days 14-28 (RI resistance). SSCP analysis indicated that these patients experienced true treatment failure. Because we observed 15 failures for the first 16 patients in our study, we can assert (95% confidence level, 80% power) that the proportion of treatment failures in this population was not significantly !25% [16] .
Identification of genetic polymorphisms at the cg2 locus. During the first half of this study, we analyzed allelic types of cg2, because cg2 then was considered to be a candidate gene for chloroquine resistance [12] . To determine whether genetic polymorphisms at cg2 predicted treatment outcome with chloroquine, day 0 isolates from patients in whom chloroquine treatment failed (
) and an equal number of isolates from n p 7 patients who were successfully cured by chloroquine were analyzed by direct sequencing (table 2). One of 7 isolates from patients in whom chloroquine therapy failed contained polymorphisms in cg2 that were previously reported to be associated with chloroquine resistance in Southeast Asia [12] . Of interest, 1 isolate contained a "7G8-like" genotype (chloroquine resistant), on the basis of partial sequence analysis of the cg2 gene. The 5 remaining in vivo resistant isolates had a genotype that included a portion of the sensitive (strain "Hb3-like") allele apparently recombined with the resistant (strain "Dd2-like") allele. One in vivo sensitive isolate carried the resistant Dd2-like allele; the remaining 6 retained a Dd2/Hb3 hybrid genotype. Therefore, 11 of 14 isolates in this locale had a novel hybrid genotype. However, neither this genotype nor those previously reported correlated with clinical outcome. Analysis of cg2 was discontinued during the second phase of this project, because it was reported during the course of this study that cg2 was not the chloroquine resistance determinant, on the basis of transfection study results [14] .
Identification of genetic polymorphisms at the pfmdr1 locus. The presence of tyrosine (Y) at position 86 of pfmdr1 is associated with chloroquine resistance [23] . By PCR-RFLP analysis, 7 in vivo resistant isolates contained the N86Y allele in pfmdr1; the other 11 resistant isolates retained the wild-type or sensitive allele (table 3) . Three of 11 in vivo sensitive isolates had the Y86 resistant allele, 7 had the wild-type N86 allele, and 1 was "mixed" (table 4). We had sufficient patients in our study for 190% power to demonstrate a correlation of pfmdr1 (N86Y) with chloroquine treatment failure equal to that found by other researchers [23] . No significant relative risk (RR) of Y86 with chloroquine treatment failure was found in this cohort (RR, 1.11; 95% CI, 0.19-7.22). Furthermore, x 2 comparison of 2 proportions did not show a significant association of Y86 with treatment failure ( , x 2 with Yates correction). Analysis of P 1 .1 posttreatment failure isolates that were initially "sensitive" at residue 86 of pfmdr1 showed that 2 of 8 amplifiable isolates had undergone a selective effect for the N86Y resistant mutation in vivo (data not shown). 
NOTE. Point mutations and repeats in cg2 previously linked to chloroquine resistance; Dd2-like (resistant) residues and k repeat are in italic type [12] . Identification of genetic polymorphisms at the pfcrt locus. We used a PCR-RFLP strategy to demonstrate the presence or absence of the T76 mutation in pfcrt that was recently associated with chloroquine resistance [14, 22] . Nested PCR amplification followed by restriction enzyme analysis indicates that ApoI digestion cuts the wild-type allele (K76) but not the mutant one (T76). Laotian isolates were analyzed, and the chloroquine-sensitive laboratory isolates (CAMP and 3D7) that bear the K76 sensitive allele and the chloroquine resistant line ITG that contains the T76 resistant allele were used as controls (figure 1). These results were confirmed by mutation-specific PCR analysis and sequencing of selected isolates (data not shown). The resistance mutation (T76) was present in all 18 in vivo resistant isolates and in 9 of 9 amplifiable in vivo sensitive isolates identified in this cohort (table 3 and table 4) .
Discussion
In our 28-day in vivo treatment trial, most (54%) falciparum infections in a region of Laos still responded to chloroquine therapy. This observation is in striking contrast to findings in neighboring countries, in which multidrug-resistant malaria predominates and where chloroquine has not been a useful therapeutic option for falciparum malaria for 12 decades. Although in vivo chloroquine-sensitive falciparum malaria still exists in Laos, high-grade (RII/RIII) resistance appears to be emerging. Furthermore, neither pfmdr1 (N86Y) nor cg2 polymorphisms were predictive of chloroquine treatment outcome in this cohort. The pfcrt point mutation (K76T) was present in 100% of the in vivo chloroquine-resistant isolates but was not predictive of treatment outcome, since it was also present in in vivo susceptible isolates.
Determining whether current malaria treatment policies are valid may be facilitated by examining the efficacy of antimalarials, such as chloroquine, in in vivo treatment trials [21] . Lack of appropriate equipment, electricity, and expertise make the microscopic diagnosis of malaria difficult in in vivo trials in rural areas. Thus, we used a combination of 2 rapid malaria diagnostic assays that detect different antigens, to unambiguously identify potential participants in the field setting for our 28-day in vivo trial [24, 25] . We found that over half of falciparum-infected patients in this region of Laos still respond to standard treatment courses of chloroquine. The rest recrudesced. On the basis of the number of failures observed, we can assert (95% confidence level, 80% power) that the prevalence of clinical failures was not significantly !25%, a prevalence frequently used as an indication to replace first-line therapy for uncomplicated malaria [16, 21] .
Chloroquine is available over the counter in most private pharmacies in Laos. Whether resistance is appearing as the result of local extensive use of chloroquine or whether drugresistant isolates are being imported from neighboring countries has yet to be determined. Of interest, unlike many other regions with emerging drug resistance, most (72%) of the chloroquine treatment failures identified were associated with high grade (RII/RIII) rather than low-grade (RI) resistance. The preponderance of resistance at RII/RIII levels contrasts with previous findings and coincides with the increased movement of people across Laotian borders in the last 5 years [4, 6] . The movement of resistant malaria in Southeast Asia has been documented (e.g., the importation of multidrug-resistant falciparum malaria across the Thai-Cambodian border) [26] . The prevalence and spread of high-grade resistance needs to be carefully monitored by Laotian public health policymakers, because adverse outcomes may escalate with the continued use of chloroquine in the presence of increasing resistance. To estimate the national scale of chloroquine-resistance, additional 28-day in vivo chloroquine treatment trials are required in various areas of Laos. A limitation of the present study was the lack of chloroquine levels to confirm absorption of drug. It is possible that a proportion of the treatment failures resulted from inadequate drug absorption and therefore in vivo chloroquine sensitivity may be somewhat higher than we estimate. It will be important to include drug levels in subsequent in vivo trials in Laos.
The surveillance of drug-resistant malaria would be greatly facilitated by the identification of reliable molecular markers of drug resistance. To be clinically and epidemiologically useful, a molecular approach for detection of resistance markers must be field applicable, and the presence of these markers must correlate with in vitro drug resistance and in vivo treatment outcome. In this study, we examined the ability of 3 putative molecular markers of chloroquine resistance to predict chloroquine treatment outcome in a population of falciparuminfected patients. A comparison of 6 point mutations and k repeats in cg2 identified a novel Dd2/Hb3 hybrid genotype in 11 (78.6%) of 14 isolates sequenced. However, no strict correlation with in vivo outcome was identified with this or other described cg2 polymorphisms. Others have reported similar findings, in that both point mutations and repetitive motifs in cg2 fail to strictly correlate with chloroquine treatment failure [27] [28] [29] [30] . Furthermore, these in vivo data support the recent finding that cg2 resistant alleles are unable to confer resistance in transfection-based studies [14] . Similarly, no strict correlation of the pfmdr1 N68Y point mutation with treatment outcome was identified. However, levels of pfmdr1 gene expression and mutations at other sites in pfmdr1 were not analyzed and may provide an alternative explanation for the lack of correlation with in vivo resistance observed in this study [31, 32] . Our data do not exclude the possibility that combinations of markers may be predictive of treatment outcome [33] .
Multiple mutations in pfcrt are associated with in vitro chloroquine resistance in a number of parasite lines [14] . In agreement with this observation, molecular analysis of the chloroquine re-sistance marker pfcrt demonstrated a perfect association with in vivo chloroquine treatment failure. However, this allele was also found in 9 of 9 amplifiable in vivo sensitive isolates. Potential explanations for the presence of the T76 mutation in in vivo sensitive isolates include inadequate follow-up to detect very late (128 days) recrudescence; unrecognized acquired immunity in this population leading to clearance of low level in vitro chloroquine resistant parasites; the possibility that K76T mutation is necessary and sufficient for in vitro chloroquine resistance but that additional mutations or changes in level of expression of other genes may be required to confer an in vivo resistant phenotype in some infections [32] ; in vivo selection for the resistant allele; and the presence of mixed infections containing sensitive and resistant alleles with in vivo selection for low-level resistant parasites. Because all isolates possessed the PfCRT resistance mutation T76 at day 0, these latter 2 possibilities are unlikely explanations for our findings.
Taken together, these findings indicate that the level of in vitro chloroquine resistance in Laos may be higher than that estimated by the in vivo outcomes we report. The presence of the T76 mutation may be necessary but not sufficient to predict in vivo treatment outcome in all patients. In vivo resistance may be influenced by a variety of factors, in addition to the K76T mutation in PfCRT, including individual variations in drug absorption, pharmacokinetics, the underlying innate and acquired immune response, and the presence of additional mutations or compensatory changes in expression of other genes that may influence the level of resistance and, ultimately, the treatment outcome of patients infected with parasites that already display the K76T mutation. Although a major advance in our understanding of chloroquine resistance, if the T76 mutation is observed in a proportion of in vivo sensitive isolates in other locations, it may limit the use of this single point mutation as a molecular marker to predict clinical outcome or for the molecular surveillance of in vivo chloroquine resistance. A more detailed analysis of PfCRT and its associated mutations is needed for a clearer understanding of its predictive value in chloroquine in vivo treatment studies in geographically diverse locations.
